Paolo Tarantino: What Is the Optimal Setting for T-DXd in Early Breast Cancer?

Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“What Is the Optimal Setting for T-DXd in Early Breast Cancer?

Thanks to The ASCO Post for highlighting the Miami Breast debate between Giuseppe Curigliano and myself, where we reviewed the pros and cons of neoadjuvant (DB-11) vs adjuvant (DB-05) T-DXd.”